Escitalopram
ApprovedCompleted 0 watching 0 views this week🔥 Hot
85
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Anxiety Disorders,Generalized Anxiety Disorder
Conditions
Anxiety Disorders,Generalized Anxiety Disorder
Trial Timeline
May 30, 2019 → Sep 20, 2021
NCT ID
NCT03924323About Escitalopram
Escitalopram is a approved stage product being developed by AbbVie for Anxiety Disorders,Generalized Anxiety Disorder. The current trial status is completed. This product is registered under clinical trial identifier NCT03924323. Target conditions include Anxiety Disorders,Generalized Anxiety Disorder.
Hype Score Breakdown
Clinical
30
Activity
20
Company
10
Novelty
10
Community
12
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03924323 | Approved | Completed |
Competing Products
20 competing products in Anxiety Disorders,Generalized Anxiety Disorder